Related Experiment Videos
Quinapril and blood lipids.
P Koskinen1, V Manninen, A Eisalo
1First Department of Medicine, University Central Hospital, Helsinki, Finland.
British Journal of Clinical Pharmacology
|October 1, 1988
Summary
Quinapril, an angiotensin-converting enzyme inhibitor, did not significantly alter blood lipid profiles in hypertensive patients. Long-term therapy also showed no adverse effects on cholesterol or triglyceride levels.
Area of Science:
- Cardiovascular Pharmacology
- Lipid Metabolism Research
Background:
- Hypertension management often involves medications that may impact lipid profiles.
- Angiotensin-converting enzyme (ACE) inhibitors are a common class of antihypertensive drugs.
Purpose of the Study:
- To evaluate the impact of quinapril on blood lipid profiles in hypertensive patients.
- To assess changes in total cholesterol, triglycerides, HDL, and LDL cholesterol.
Main Methods:
- A randomized, placebo-controlled study involving 23 hypertensive patients.
- Patients received either quinapril hydrochloride or a placebo for 12 weeks.
- Lipid profiles were analyzed at baseline and after treatment.
Main Results:
- No significant changes in serum total cholesterol or triglycerides were observed after 12 weeks.
- High-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol levels remained stable.
- Extended therapy up to 1 year in a subset of patients showed no unfavorable lipid profile changes.
Conclusions:
- Quinapril therapy does not adversely affect blood lipid profiles in hypertensive individuals.
- ACE inhibition with quinapril appears safe concerning lipid metabolism.
- These findings support the use of quinapril in hypertensive patients without lipid concerns.